Patent · US Expired

6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt

US7304084B2 · kind B2 · utility

0Cited by

4References

4Claims

0Family size

Assignee

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · US

Inventors

Jared Lynn Randall · North Bend, US
Richard Gibbs · Norwich, US
Gregory Kent Bosch · Sharonville, US
Michael David Curtis · Norwich, US
Li Sun · Fremont, US
Nicholas Nikolaides · Mason, US

Key dates

Filing date	Jan 17, 2006
Grant date	Dec 4, 2007
Priority date	—
Expiry date	Jan 17, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D235/06
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile substantially free of 2,3,7-triamino-4,6-dimethyl-1,9-phenazinedicarbonitrile, and the anhydrous monoacetate salt thereof, are useful in the treatment of alpha-2 mediated disorders such as ocular hypertension.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.